Vis enkel innførsel

dc.contributor.authorVervaart, Mathyn Adrianus Marinus
dc.contributor.authorStrong, Mark
dc.contributor.authorClaxton, Karl
dc.contributor.authorWelton, Nicky
dc.contributor.authorWisløff, Torbjørn
dc.contributor.authorAas, Eline
dc.date.accessioned2022-02-26T14:42:19Z
dc.date.available2022-02-26T14:42:19Z
dc.date.issued2021-12-30
dc.description.abstractBackground - Decisions about new health technologies are increasingly being made while trials are still in an early stage, which may result in substantial uncertainty around key decision drivers such as estimates of life expectancy and time to disease progression. Additional data collection can reduce uncertainty, and its value can be quantified by computing the expected value of sample information (EVSI), which has typically been described in the context of designing a future trial. In this article, we develop new methods for computing the EVSI of extending an existing trial’s follow-up, first for an assumed survival model and then extending to capture uncertainty about the true survival model.<p> <p>Methods - We developed a nested Markov Chain Monte Carlo procedure and a nonparametric regression-based method. We compared the methods by computing single-model and model-averaged EVSI for collecting additional follow-up data in 2 synthetic case studies.<p> <p>Results - There was good agreement between the 2 methods. The regression-based method was fast and straightforward to implement, and scales easily to include any number of candidate survival models in the model uncertainty case. The nested Monte Carlo procedure, on the other hand, was extremely computationally demanding when we included model uncertainty.<p> <p>Conclusions - We present a straightforward regression-based method for computing the EVSI of extending an existing trial’s follow-up, both where a single known survival model is assumed and where we are uncertain about the true survival model. EVSI for ongoing trials can help decision makers determine whether early patient access to a new technology can be justified on the basis of the current evidence or whether more mature evidence is needed.en_US
dc.identifier.citationVervaart, Strong, Claxton, Welton, Wisløff, Aas. An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial. Medical decision making. 2021en_US
dc.identifier.cristinIDFRIDAID 1979801
dc.identifier.doi10.1177/0272989X211068019
dc.identifier.issn0272-989X
dc.identifier.issn1552-681X
dc.identifier.urihttps://hdl.handle.net/10037/24170
dc.language.isoengen_US
dc.publisherSAGE Publicationsen_US
dc.relation.journalMedical decision making
dc.relation.projectIDNordforsk: 298854en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleAn Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trialen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel